Venezuela Tecnovigilancia 2026: Adverse Event Reporting and SACS Oversight

1. Key takeaways

Within SACS, the directorate responsible for the regulation and control of materials, equipment, establishments and health professions hosts an internal Inspection and Tecnovigilancia department. Tecnovigilancia is the post-market surveillance and adverse event reporting function for medical devices, and it sits inside the regulator rather than being delegated to industry bodies.

The conclusion is this: the fact that technovigilance exists as an internal function of the regulator means adverse event monitoring in Venezuela is a mandatory obligation, not a voluntary commitment. A manufacturer cannot decide whether to build a technovigilance system; it can only decide how to build one. That reframing changes the budget conversation, because a voluntary programme can be scoped down to what the business considers proportionate, while a mandatory one is measured against an external standard set by the authority that will inspect it.

A second point follows from the first. Because the function is staffed and permanent, its expectations are also stable. Requirements may be confirmed at the receiving window rather than read off a published guideline, but the existence of the function, its remit and its enforcement capacity are not in doubt. Planning should therefore assume continuous operation rather than periodic campaigns.

2. Legal basis

Position statement: the specific reporting timelines, reporting forms and severity classification for technovigilance were not traced in this verification to a Venezuelan official instrument that can be cited directly, and are marked as a practical estimate. Current requirements must be confirmed at the receiving window before execution.

Read together, the four instruments describe a function built in layers. Decreto N° 472 of 1994 supplied the original supervisory grant; the health organization law of 1998 supplied the statutory basis for regulating health products; the 2006 organic regulation supplied the organizational home; and the 2026 circular supplied the current policy direction. Nothing in this sequence creates a reporting form. That gap between an established function and an unpublished procedure is the single most important practical feature of the Venezuelan technovigilance landscape.

The department’s remit also follows from its name, and the two halves are worth separating. Inspection covers the establishments that handle devices, including storage, records and distribution practice. Technovigilance covers the behaviour of the devices themselves once they are in use. Because both sit in the same unit, a single visit can test the physical chain and the information chain together: whether the goods in the warehouse match the records, and whether the incidents reported from the field were evaluated and passed on. Manufacturers should expect the two lines of questioning to converge rather than to be handled as separate exercises.

3. Expert insights

1. The internal placement of the function is itself the signal. When a regulator makes a specific post-market function into a standing department, that function acquires dedicated staff, routine workflows and inspection and enforcement capacity. This differs fundamentally from a legal requirement with no executing body, because the latter tends in practice to remain formal while the former does not. Practitioners who have worked in markets where technovigilance obligations exist only on paper will recognise the difference immediately: in Venezuela the obligation has somewhere to be enforced from.

2. Circular DGSACS-008/2026 gives technovigilance policy-level backing. The circular explicitly requires that health risk be minimized, that traceability be safeguarded, and that the public be able to identify a product’s origin and manufacturing information. These objectives align closely with the purpose of adverse event monitoring, which indicates that technovigilance is on an upward trajectory in the current regulatory priority order. For planning purposes this argues against deferring system build-out: a function moving up the priority order is a poor candidate for a later budget cycle.

3. The reporting route has to be designed around the position of the license holder. Because SACS interfaces with the license holder (articles 31 and 32 of this series) and not with the foreign manufacturer, the collection and reporting chain runs health institution or user, then importer or distributor, then license holder, then SACS. The manufacturer sits upstream of that chain, and whether information reaches the license holder in time depends on the terms of the agreement with that holder, not on how well the manufacturer’s own system is built. A flawless internal vigilance process is worth nothing in Venezuela if the contractual route for passing a case across the border is undefined.

4. A global vigilance system needs local adaptation. Most multinational manufacturers already operate a global adverse event reporting system, but that system is normally designed around European MDR or United States FDA timelines and severity categories. Where Venezuelan timelines and categories differ, a mapping rule has to be written: which events are reportable to SACS, within what period, on what form, and who signs. The global system cannot be assumed to cover Venezuelan obligations automatically, and the reconciliation is a documentation exercise, not an IT configuration.

4. Practical recommendations

1. Manufacturers and license holders: specify in the license holder agreement the collection of adverse event information, the transmission deadline, the allocation of reporting responsibility and the duty to cooperate.
2. Regulatory affairs leads: write a mapping rule from the global vigilance system to Venezuela, defining which events are reportable to SACS, the reporting deadline and the format.
3. Quality teams: archive reporting records together with post-market safety data so that they serve the renewal directly (article 41 of this series).
4. Clinical and post-market teams: for implantable and high-risk devices, establish proactive follow-up to compensate for the limits of passive reporting (article 18 of this series).

5. Verification checklist

• □ The license holder agreement specifies the collection and transmission deadlines for adverse event information
• □ A mapping rule from the global vigilance system to Venezuela has been established
• □ Reporting timelines and formats for technovigilance have been confirmed at the receiving window (practical estimate)
• □ Reporting records have been incorporated into the renewal file
• □ A proactive follow-up mechanism exists for high-risk products

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN supports medical device and IVD manufacturers, importers and authorized representatives with registration and post-market compliance in Venezuela: dossier preparation and filing through the SACS and COMEX channels, license-holder coordination, technovigilance and adverse event workflows, recall and field corrective action planning, inspection readiness, and continuous monitoring of circulares and decrees. For tailored support on your Venezuela portfolio, contact the GRZAN regulatory team at info@grzanglobal.com.